Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
BMJ Open|July 16, 2024
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristoneRalph A DeFronzo, Richard J Auchus, Irina Bancos, et al.
The Oncologist|March 13, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA TrialSara A Hurvitz, Anthony Gonçalves, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.
JNCI Cancer Spectrum|April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care ChemotherapyHope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.
The New England Journal of Medicine|January 24, 2014
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's diseaseStephen Salloway, Reisa Sperling, Nick C Fox, et al.
Neurology|July 26, 2015
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trialsEnchi Liu, Mark E Schmidt, Richard Margolin, et al.
JACC. Advances|February 17, 2026
Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and DesignJorge Plutzky, Pam R Taub, Deepak L Bhatt, et al.
Diabetes Care|June 23, 2025
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone TreatmentRalph A DeFronzo, Vivian Fonseca, Vanita R Aroda, et al.
Diabetes Care|April 18, 2025
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 DiabetesJohn B Buse, Steven E Kahn, Vanita R Aroda, et al.
The Lancet. Diabetes & Endocrinology|February 23, 2026
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal studyRosario Pivonello, Giorgio Arnaldi, Richard J Auchus, et al.
Pageof 4